PSTV has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
PSTV has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.
Plus Therapeutics's adjusted book value per share for the three months ended in Dec. 2023 was $-0.303. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $453.44 for the trailing ten years ended in Dec. 2023.
During the past 12 months, Plus Therapeutics's average Cyclically Adjusted Book Growth Rate was -26.00% per year. During the past 3 years, the average Cyclically Adjusted Book Growth Rate was -48.20% per year. During the past 5 years, the average Cyclically Adjusted Book Growth Rate was -45.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.
During the past 13 years, the highest 3-Year average Cyclically Adjusted Book Growth Rate of Plus Therapeutics was 92.50% per year. The lowest was -55.10% per year. And the median was -48.40% per year.
As of today (2024-04-27), Plus Therapeutics's current stock price is $1.69. Plus Therapeutics's Cyclically Adjusted Book per Share for the quarter that ended in Dec. 2023 was $453.44. Plus Therapeutics's Cyclically Adjusted PB Ratio of today is 0.00.
During the past 13 years, the highest Cyclically Adjusted PB Ratio of Plus Therapeutics was 268.48. The lowest was 0.01. And the median was 0.07.
The historical data trend for Plus Therapeutics's Cyclically Adjusted Book per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Plus Therapeutics Quarterly Data | ||||||||||||||||||||
Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | |
Cyclically Adjusted Book per Share | Get a 7-Day Free Trial | 612.92 | 501.51 | 441.48 | 611.67 | 453.44 |
For the Biotechnology subindustry, Plus Therapeutics's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Plus Therapeutics's Cyclically Adjusted PB Ratio distribution charts can be found below:
* The bar in red indicates where Plus Therapeutics's Cyclically Adjusted PB Ratio falls into.
E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.
What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?
Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.
If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.
We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.
Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.
For example, Plus Therapeutics's adjusted Book Value per Share data for the three months ended in Dec. 2023 was:
Adj_Book | = | Book Value per Share | / | CPI of Dec. 2023 (Change) | * | Current CPI (Dec. 2023) |
= | -0.303 | / | 129.4194 | * | 129.4194 | |
= | -0.303 |
Current CPI (Dec. 2023) = 129.4194.
Plus Therapeutics Quarterly Data
Book Value per Share | CPI | Adj_Book | |
201403 | 3,431.429 | 99.695 | 4,454.543 |
201406 | 1,612.162 | 100.560 | 2,074.842 |
201409 | -4,221.795 | 100.428 | -5,440.547 |
201412 | -6,131.183 | 99.070 | -8,009.452 |
201503 | -21,882.075 | 99.621 | -28,427.361 |
201506 | 1,602.837 | 100.684 | 2,060.292 |
201509 | 3,378.378 | 100.392 | 4,355.226 |
201512 | 6,706.593 | 99.792 | 8,697.689 |
201603 | 4,162.903 | 100.470 | 5,362.379 |
201606 | 6,857.509 | 101.688 | 8,727.616 |
201609 | 5,007.326 | 101.861 | 6,362.053 |
201612 | 3,801.384 | 101.863 | 4,829.764 |
201703 | 2,322.713 | 102.862 | 2,922.396 |
201706 | 2,529.279 | 103.349 | 3,167.302 |
201709 | 1,688.769 | 104.136 | 2,098.797 |
201712 | 1,686.122 | 104.011 | 2,098.015 |
201803 | 1,031.630 | 105.290 | 1,268.056 |
201806 | 577.278 | 106.317 | 702.720 |
201809 | 393.714 | 106.507 | 478.413 |
201812 | 264.289 | 105.998 | 322.687 |
201903 | 132.044 | 107.251 | 159.338 |
201906 | -212.458 | 108.070 | -254.431 |
201909 | 0.845 | 108.329 | 1.010 |
201912 | 4.484 | 108.420 | 5.352 |
202003 | 0.329 | 108.902 | 0.391 |
202006 | 11.582 | 108.767 | 13.781 |
202009 | 8.563 | 109.815 | 10.092 |
202012 | 6.736 | 109.897 | 7.933 |
202103 | 14.017 | 111.754 | 16.233 |
202106 | 14.823 | 114.631 | 16.735 |
202109 | 14.409 | 115.734 | 16.113 |
202112 | 10.480 | 117.630 | 11.530 |
202203 | 9.894 | 121.301 | 10.556 |
202206 | 6.462 | 125.017 | 6.690 |
202209 | 5.252 | 125.227 | 5.428 |
202212 | 2.877 | 125.222 | 2.973 |
202303 | 1.111 | 127.348 | 1.129 |
202306 | 0.924 | 128.729 | 0.929 |
202309 | 0.580 | 129.860 | 0.578 |
202312 | -0.303 | 129.419 | -0.303 |
Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.
If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.
For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.
The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.
Plus Therapeutics's Cyclically Adjusted PB Ratio of today is calculated as
Cyclically Adjusted PB Ratio | = | Share Price | / | Cyclically Adjusted Book per Share |
= | 1.69 | / | 453.44 | |
= | 0.00 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
During the past 13 years, the highest Cyclically Adjusted PB Ratio of Plus Therapeutics was 268.48. The lowest was 0.01. And the median was 0.07.
Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.
Thank you for viewing the detailed overview of Plus Therapeutics's Cyclically Adjusted Book per Share provided by GuruFocus.com. Please click on the following links to see related term pages.
Marc H Hedrick | officer: President | C/O CYTORI THERAPEUTICS, INC., 3020 CALLAN ROAD, SAN DIEGO CA 92121 |
Robert P Lenk | director | LUNA INNOVATIONS INCORPORATED, 2851 COMMERCE STREET, BLACKSBURG VA 24060 |
Howard Clowes | director | 217 DWIGHT ROAD, BURLINGAME CA 94010 |
Greg Petersen | director | 3100 MAIN STREET, SUITE 900, HOUSTON TX 77002 |
Sims Andrew John Hugh Macintyre | officer: Chief Financial Officer | 4200 MARATHON BOULEVARD, SUITE 200, AUSTIN TX 78756 |
Norman D. Lafrance | officer: CHIEF MEDICAL OFFICER | MOLECULAR INSIGHT PHARMCEUTICALS, INC., 160 SECOND STREET, CAMBRIDGE MA 02142 |
Es-johansson An Van | director | 6863 BEE CAVE ROAD, SUITE 200, AUSTIN TX 78736 |
Ag Postfinance | 10 percent owner | MINGERSTRASSE 20, BERN V8 3030 |
Bank Sa Swissquote | 10 percent owner | CHEMIN DE LA CRETAUX 33, GLAND V8 1196 |
Anthony Gregg Lapointe | director | PO BOX 83216, GAITHERSBURG MD 20883-3216 |
Ron Martell | director | PONIARD PHARMACEUTICALS, INC., 750 BATTERY STREET, SUITE 330, SAN FRANCISCO CA 94111 |
Mark Marino | officer: Chief Medical Officer | C/O CYTORI THERAPEUTICS, INC., 3020 CALLAN ROAD, SAN DIEGO CA 92121 |
John David Harris | officer: VP and GM of Cell Therapy | 3020 CALLAN ROAD, SAN DIEGO CA 92121 |
Gail K Naughton | director | C. R. BARD, INC., 730 CENTRAL AVENUE, MURRAY HILL NJ 07974 |
David Rickey | director |
From GuruFocus
By sperokesalga sperokesalga • 05-02-2023
By Marketwired • 11-03-2023
By Marketwired • 06-29-2023
By sperokesalga sperokesalga • 05-12-2023
By Marketwired • 09-11-2023
By sperokesalga sperokesalga • 04-28-2023
By GuruFocus Research • 09-15-2023
By Marketwired • 11-03-2023
By Marketwired • 10-31-2023
By Marketwired • 10-23-2023